Treatment of climacteric symptoms in breast cancer patients: a retrospective study from a medication databank.

[1]  S. Davis,et al.  Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis , 2014, Menopause.

[2]  S. L'espérance,et al.  Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations , 2013, Supportive Care in Cancer.

[3]  L. Mariani,et al.  Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy , 2013, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[4]  J. Bergquist,et al.  Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients , 2012, Climacteric : the journal of the International Menopause Society.

[5]  G. D. de Bock,et al.  The management of menopausal symptoms in breast cancer survivors: case-based approach. , 2012, Maturitas.

[6]  M. Dowsett,et al.  Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. , 2012, Journal of oncology practice.

[7]  S. Pruthi,et al.  Current Overview of the Management of Urogenital Atrophy in Women with Breast Cancer , 2011, The breast journal.

[8]  C. Loprinzi,et al.  International Journal of Women's Health Dovepress Management of Menopause-associated Vasomotor Symptoms: Current Treatment Options, Challenges and Future Directions , 2022 .

[9]  L. Holmberg,et al.  Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. , 2008, Journal of the National Cancer Institute.

[10]  F. Liebens,et al.  A survey among breast cancer survivors: treatment of the climacteric after breast cancer , 2008, Climacteric : the journal of the International Menopause Society.

[11]  F. Liebens,et al.  Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review , 2007, Climacteric : the journal of the International Menopause Society.

[12]  F. Liebens,et al.  Safety of hormone therapy after breast cancer: a qualitative systematic review. , 2006, Human reproduction.

[13]  M. Dowsett,et al.  Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Thacker,et al.  Menopausal hormone therapy (HT) in patients with breast cancer. , 2006, Maturitas.

[15]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[16]  M. Hickey,et al.  Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. , 2005, The Lancet. Oncology.

[17]  David W. Fisher,et al.  A Time for Change? , 2005 .

[18]  R. Chlebowski,et al.  Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence , 2005, Breast Cancer Research.

[19]  L. Rutqvist,et al.  Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. , 2005, Journal of the National Cancer Institute.

[20]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[21]  L. Holmberg,et al.  HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped , 2004, The Lancet.

[22]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[23]  L. Kestin,et al.  Estrogen replacement therapy in breast cancer survivors: a matched-controlled series , 2003, Menopause.

[24]  Terry L. Smith,et al.  Estrogen replacement therapy for menopausal women with a history of breast carcinoma , 2002, Cancer.

[25]  P. Remington,et al.  Prevalence and treatment of menopausal symptoms among breast cancer survivors. , 2002, Journal of pain and symptom management.

[26]  P. Hietanen,et al.  A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy. , 2001, Maturitas.

[27]  J. Cuzick,et al.  Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. , 2001, British journal of cancer.

[28]  R. Tummala,et al.  The risk of premature menopause induced by chemotherapy for early breast cancer. , 1999, Journal of women's health & gender-based medicine.

[29]  P. Goodwin,et al.  Risk of menopause during the first year after breast cancer diagnosis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Espié,et al.  [Hormonal replacement therapy in menopause after breast cancer: first french study]. , 1998, Contraception, fertilite, sexualite.

[31]  P. Ganz,et al.  Life after breast cancer: understanding women's health-related quality of life and sexual functioning. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Helzlsouer,et al.  Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N. Robert,et al.  Estrogen Replacement Therapy in Breast Cancer Survivors-Reply , 1995 .

[34]  N. Robert,et al.  Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. , 1994, JAMA.

[35]  N. Robert,et al.  Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change , 1994 .

[36]  H. Johansson,et al.  Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. , 2013, European journal of cancer.